On April 26, Novartis China announced that its innovative drug Feiheda (ipcopam hydrochloride capsules) has been approved by China's National Drug Administration to treat adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have not previously been treated with complement inhibitors. Ipcopam hydrochloride capsules are the world's first specific complement factor B oral inhibitor, and the first oral monotherapy for adult PNH treatment. PNH is a rare chronic, progressive, and life-threatening hematologic disease. The main clinical symptoms include anemia, paroxysmal hemoglobinuria, bone marrow hematopoietic failure, and thrombosis. PNH can occur at any age, but is more common in people aged 30-40 years. Currently, the standard treatment for PNH is anti-complement C5 therapy, but after receiving treatment, most patients still have residual anemia, fatigue, and blood transfusion dependence. (Surge News)
诺华罕见病创新药国内获批，系成人PNH治疗的首个口服单药疗法
Novartis's innovative drug for rare diseases has been approved domestically. It is the first oral monotherapy for PNH treatment in adults
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.